Dr Sud Speaks, page-6

Well said, IHL is categorically one of the most professional outfits I’ve invested in with massive potential.

The ethics approval for Obstructive Sleep Apnoea in partnership with the Alfred Hospital is due soon and this in-human phase 2 trial could be a company maker.

Efficacy simply needs to be “in the ball park” compared to CPAP because there is no pharmacotherapy alternative. Tolerability is important, however those who follow cannabis research closely know that it is a very safe compound. Epidiolex (GW Pharma) is a CBD based drug which is safe to prescribe to 2 year old children.

As Dr Agarwal inferred, the value created by a successful phase 2 OSA result will be of huge economic interest to big pharmaceutical because it potentially disrupts a multi billion dollar sector dominated by CPAP.

It’s not surprising that IHL is attracting investors like Glenn Poswell (Ex-Packer family fund manager) who recently acquired a substantial position in the company along with an undisclosed entity. Nearly 50 million shares.